Your session is about to expire
← Back to Search
Study Summary
This trial is testing whether a medicine called BI 425809 improves learning and memory in people with schizophrenia. People with schizophrenia have difficulty with mental functioning, such as memory and attention. The trial will last 8 months and involve 14 visits to the study site.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 611 Patients • NCT02788513Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've been on the same antipsychotic medication for at least 12 weeks.I have been on the same psychoactive medication, except anticholinergics, for at least 12 weeks and on the current dose for at least 35 days.I am taking two antipsychotics, and both are within the recommended dose limits.I have been on the same psychoactive medication, except anticholinergics, for at least 12 weeks and on the current dose for over 35 days.I am using or willing to use effective birth control and agree to pregnancy tests.I have cognitive issues due to a condition like epilepsy, stroke, or head injury.My side effects from antipsychotic medication can't be managed with low-dose treatments.I have not undergone electroconvulsive therapy.I am stable and not in the acute phase of my illness.I haven't been hospitalized or needed more psychiatric care for my schizophrenia in the last 12 weeks.I've been on 1 or 2 antipsychotics (not clozapine) for over 12 weeks and on the same dose for at least 35 days.I am on a stable dose of my antipsychotic medication, even if the form has changed.I have been on the same psychoactive medication, except anticholinergics, for at least 12 weeks.I take 1 mg or less of lorazepam-equivalent daily.I haven't had certain treatments in the last 6 months.I am between 18 and 50 years old.I have trouble with daily tasks like talking, focusing, remembering, or navigating.I meet with my study partner at least once a week in person.I am taking two antipsychotics, and both are within the recommended dose limits.I have schizophrenia, am stable, and struggle with daily activities.I am using or willing to use effective birth control and agree to pregnancy tests during the trial.Women who might be able to have children must use contraception that works very well.I've been on 1 or 2 antipsychotics (not clozapine) for at least 12 weeks.I take no more than 1 mg of lorazepam or its equivalent daily.Patients should have difficulty completing day-to-day activities as determined by the investigator.The study partner should be someone who interacts with the patient on a regular basisMy schizophrenia is stable, and I haven't been hospitalized for it in the last 12 weeks.There are more requirements to participate in the study.I am not taking clozapine.I have used ketamine or esketamine.I am currently taking stimulant medications.I am not taking more than the recommended dose of any psychoactive medication.I have a mental health diagnosis other than Schizophrenia.I am between 18 and 50 years old.I have been diagnosed with schizophrenia.
- Group 1: Iclepertin
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Will this trial be inclusive of patients who are over the age of seventy?
"According to the eligibility requirements listed on the clinical trial, patients must be aged 18-50. There are 47 studies dedicated to those under 18 and 174 for seniors above 65 years old."
Are there certain restrictions for who can participate in this research study?
"This research is looking for 586 individuals with a diagnosis of schizophrenia that fall between the ages of 18-50. The most crucial inclusion criteria are as follows: Patients must have functional impairment in day-to-day activities per investigator judgement, be clinically stable and in the residual (non-acute) phase of their illness with no hospitalization or uncontrolled positive symptoms, maintained on current antipsychotic treatment for at least 12 weeks and on current dose for at least 35 days prior to randomization, use highly effective methods of birth control if they are women of childbearing potential, have a study partner who interacts with them regularly."
What is the safety profile of BI 425809?
"BI 425809 is in Phase 3 clinical trials, signifying that while there is data documenting the efficacy of the medication, multiple rounds of testing have verified its safety. Consequently, our team at Power rates BI 425809 as a 3 on our safety scale."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger